149 of 150
Decision drift
Quiet no-decision is forming before teams hear a clean objection. In the current 150-company batch it appeared in 149 companies and ranked first in 74.
Research
Public proof for the blockers that keep stalling the buying decision
This library exists to help a cold visitor recognize a recurring blocker, see how teams usually misread it, and understand why the exact diagnosis still belongs in the private brief.
148 of 150
Trust artifacts
Buyer-grade proof is deciding who even gets a clean comparison. In the current 150-company batch it appeared in 148 companies and ranked first in 41.
126 of 150
Pricing ambiguity
Pricing interpretation cost is still a real buying blocker. In the current 150-company batch it appeared in 126 companies and ranked first in 10.
Latest dispatch
What surfaced most recently
Fresh dispatches are useful when they tell the buyer what is recurring now and what usually gets misread before the team changes the wrong thing.
Recurring blockers
Canonical explanations for the problems that keep returning
Decision drift
Quiet no-decision is forming before teams hear a clean objection. In the current 150-company batch it appeared in 149 of 150 companies and ranked as the highest-leverage issue in 74 of 150.
- Current published corpus
- 149 of 150
- Published history
- 1 cohort
Pricing ambiguity
Pricing interpretation cost is still a real buying blocker. In the current 150-company batch it appeared in 126 of 150 companies and ranked as the highest-leverage issue in 10 of 150.
- Current published corpus
- 126 of 150
- Published history
- 1 cohort
Switching friction
Migration cost and replacement anxiety are blocking otherwise credible evaluations. In the current 150-company batch it appeared in 106 of 150 companies and ranked as the highest-leverage issue in 18 of 150.
- Current published corpus
- 106 of 150
- Published history
- 1 cohort
Trust artifacts
Buyer-grade proof is deciding who even gets a clean comparison. In the current 150-company batch it appeared in 148 of 150 companies and ranked as the highest-leverage issue in 41 of 150.
- Current published corpus
- 148 of 150
- Published history
- 1 cohort
Publication history
New research should add, not replace
Each published cohort stays visible. That lets the site show what is genuinely new, while the canonical blocker pages continue to roll up the broader pattern.
Boundary
Public research stops before the company-specific diagnosis
These pages are intentionally abstracted. They prove recurrence, consequence, and the cost of misreading a blocker without exposing company identities, contacts, private outreach context, or the exact intervention path that belongs in the brief.